Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Evogene (NASDAQ: EVGN) has completed the previously announced sale of its ag-biologicals subsidiary Lavie Bio to ICL Group (NYSE: ICL). The transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, microbial bank, development pipeline, commercial products, and core personnel. Additionally, Evogene has divested its MicroBoost AI Tech-Engine for Agriculture to ICL.
The deal excludes Lavie Bio's existing strategic partnerships and commercial agreements, which will continue to generate potential future revenues for Lavie Bio's shareholders. This strategic move aligns with Evogene's goal to unlock subsidiary value while strengthening ICL's position in the global ag-biologicals market.
Evogene (NASDAQ: EVGN) ha completato la vendita precedentemente annunciata della sua controllata nel settore degli agrobiologici, Lavie Bio, al Gruppo ICL (NYSE: ICL). L'operazione comprende il trasferimento della piattaforma tecnologica proprietaria Biology Driven Design (BDD) di Lavie Bio, della banca microbica, del portafoglio di sviluppo, dei prodotti commerciali e del personale chiave. Inoltre, Evogene ha ceduto a ICL il suo MicroBoost AI Tech-Engine per l'agricoltura.
L'accordo esclude le partnership strategiche e i contratti commerciali esistenti di Lavie Bio, che continueranno a generare potenziali ricavi futuri per gli azionisti di Lavie Bio. Questa mossa strategica 猫 in linea con l'obiettivo di Evogene di valorizzare la controllata, rafforzando al contempo la posizione di ICL nel mercato globale degli agrobiologici.
Evogene (NASDAQ: EVGN) ha completado la venta previamente anunciada de su subsidiaria de agrobiol贸gicos Lavie Bio al Grupo ICL (NYSE: ICL). La transacci贸n incluye la transferencia de la plataforma tecnol贸gica propietaria Biology Driven Design (BDD) de Lavie Bio, el banco microbiano, la cartera de desarrollo, los productos comerciales y el personal clave. Adem谩s, Evogene ha vendido a ICL su Motor Tecnol贸gico MicroBoost AI para Agricultura.
El acuerdo excluye las asociaciones estrat茅gicas y los contratos comerciales existentes de Lavie Bio, que continuar谩n generando ingresos potenciales futuros para los accionistas de Lavie Bio. Esta maniobra estrat茅gica est谩 alineada con el objetivo de Evogene de desbloquear el valor de su subsidiaria, mientras fortalece la posici贸n de ICL en el mercado global de agrobiol贸gicos.
Evogene (NASDAQ: EVGN)電� 鞚挫爠鞐� 氚滍憸頃� 雴嶌儩氍柬暀 鞛愴殞靷� Lavie Bio鞚� ICL 攴鸽９ (NYSE: ICL)鞐� 雽�頃� 毵り皝鞚� 鞕勲頄堨姷雼堧嫟. 鞚措矆 瓯半灅鞐愲姅 Lavie Bio鞚� 霃呾瀽鞝侅澑 Biology Driven Design (BDD) 旮办垹 頂岆灚韽�, 氙胳儩氍� 鞚�頄�, 臧滊皽 韺岇澊頂勲澕鞚�, 靸侅梾 鞝滍拡 氚� 頃奠嫭 鞚鸽牓鞚� 鞚挫爠鞚� 韽暔霅╇媹雼�. 霕愴暅 Evogene電� 雴嶌梾鞖� MicroBoost AI 旮办垹 鞐旍鞚� ICL鞐� 毵り皝頄堨姷雼堧嫟.
鞚措矆 瓯半灅電� Lavie Bio鞚� 旮办〈 鞝勲灥鞝� 韺岉姼雱堨嫮瓿� 靸侅梾 瓿勳暯鞚� 鞝滌櫢頃橂┌, 鞚措摛鞚� 瓿勳啀頃挫劀 Lavie Bio 欤检＜霌れ棎瓴� 鞛犾灛鞝侅澑 氙鸽灅 靾橃澋鞚� 彀届稖頃� 瓴冹瀰雼堧嫟. 鞚� 鞝勲灥鞝� 臁办箻電� 鞛愴殞靷潣 臧�旃橂ゼ 攴闺寑頇旐晿氅挫劀 ICL鞚� 旮�搿滊矊 雴嶌儩氍柬暀 鞁滌灔 雮� 鞛呾毳� 臧曧檾頃橂牑電� Evogene鞚� 氇╉憸鞕� 攵�頃╉暕雼堧嫟.
Evogene (NASDAQ : EVGN) a finalis茅 la vente pr茅c茅demment annonc茅e de sa filiale en agrobiologie Lavie Bio au groupe ICL (NYSE : ICL). La transaction comprend le transfert de la plateforme technologique propri茅taire Biology Driven Design (BDD) de Lavie Bio, de sa banque microbienne, de son pipeline de d茅veloppement, de ses produits commerciaux et de son personnel cl茅. De plus, Evogene a c茅d茅 脿 ICL son MicroBoost AI Tech-Engine pour l鈥檃griculture.
L鈥檃ccord exclut les partenariats strat茅giques existants et les contrats commerciaux de Lavie Bio, qui continueront de g茅n茅rer des revenus potentiels futurs pour les actionnaires de Lavie Bio. Cette d茅marche strat茅gique s鈥檌nscrit dans l鈥檕bjectif d鈥橢vogene de valoriser sa filiale tout en renfor莽ant la position d鈥橧CL sur le march茅 mondial des agrobiologiques.
Evogene (NASDAQ: EVGN) hat den zuvor angek眉ndigten Verkauf seiner Agrarbiologie-Tochtergesellschaft Lavie Bio an die ICL Group (NYSE: ICL) abgeschlossen. Die Transaktion umfasst die 脺bertragung der propriet盲ren Biology Driven Design (BDD) Technologieplattform von Lavie Bio, der mikrobiellen Bank, der Entwicklungspipeline, der Handelsprodukte und des Kernpersonals. Zus盲tzlich hat Evogene seine MicroBoost AI Tech-Engine f眉r die Landwirtschaft an ICL ver盲u脽ert.
Der Deal schlie脽t die bestehenden strategischen Partnerschaften und Handelsvereinbarungen von Lavie Bio aus, die weiterhin potenzielle zuk眉nftige Einnahmen f眉r die Aktion盲re von Lavie Bio generieren werden. Dieser strategische Schritt steht im Einklang mit Evogenes Ziel, den Wert der Tochtergesellschaft freizusetzen und gleichzeitig die Position von ICL auf dem globalen Markt f眉r Agrarbiologie zu st盲rken.
- Strategic divestment aligned with Evogene's goal to unlock subsidiary value
- Lavie Bio retains existing strategic partnerships and commercial agreements
- Integration with ICL's global reach and operational expertise enhances market potential
- Strengthens ICL's end-to-end innovation pipeline in sustainable agriculture
- Evogene loses direct control over valuable ag-biologicals technology and IP
- Transfer of core personnel could impact Evogene's internal expertise
Insights
Evogene's sale of Lavie Bio's assets to ICL represents a strategic pivot, monetizing its bio-ag division while retaining potential revenue from existing partnerships.
Evogene has successfully completed the previously announced transaction to sell most of Lavie Bio's assets and activities to ICL Group. The deal includes Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, development pipeline, commercial products, and core personnel. Additionally, Evogene has transferred its MicroBoost AI Tech-Engine for Agriculture to ICL for additional consideration.
What's particularly noteworthy is that Lavie Bio's existing strategic partnerships and commercial agreements were excluded from the transaction and will remain under Lavie Bio's ownership. This strategic decision allows Evogene to potentially benefit from future revenues generated through these partnerships while divesting the operational aspects of the business.
This transaction aligns with Evogene's broader strategy of unlocking value from its subsidiaries. For a computational biology company like Evogene, which operates through multiple subsidiaries in different life-science domains, this divestiture represents a significant strategic pivot. By monetizing its agricultural biologicals division while maintaining certain revenue rights, Evogene can potentially redirect resources toward other divisions in its portfolio.
For ICL, a global leader in agricultural technology, this acquisition strengthens its position in the growing ag-biologicals market by integrating Lavie Bio's innovative discovery platform with ICL's global distribution network and R&D expertise. This vertical integration enhances ICL's ability to develop and commercialize sustainable agricultural solutions at scale.
REHOVOT,
Pursuant to the definitive agreement originally announced on April 21, 2025, ICL has acquired Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, microbial bank, pipeline of advanced development programs, and current commercial product offerings. In addition, Lavie Bio's core personnel will transfer to ICL. Concurrently, Evogene has divested its MicroBoost AI Tech-Engine for Agriculture, a computational engine designed to optimize microbial discovery and development through artificial intelligence, for additional consideration.
It is important to note that听Lavie Bio's existing strategic partnerships and commercial agreements are not part of this transaction and will remain under Lavie Bio's ownership. These agreements may yield future revenues for the benefit of Lavie Bio's shareholders.
Ofer Haviv, Chief Executive Officer of Evogene, stated: "The successful completion of this transaction with ICL, a global leader in agricultural technology and crop nutrition, represents a strategic milestone for Evogene. We believe that combining Lavie Bio's innovative capabilities with ICL's global reach and operational expertise will significantly advance the ag-biologicals sector and contribute to the development of sustainable agricultural solutions. This divestment is in line with our broader corporate strategy to unlock the intrinsic value of our subsidiaries and technology."
Dr.听Elinor Erez, VP R&D of Growing Solutions, ICL,听stated: "This strategic acquisition of Lavie Bio reflects ICL's continued drive to lead the global ag-biologicals market. By integrating Lavie Bio's platform with ICL's R&D expertise in plant nutrition solutions, global sales network, and field-based agronomy teams, we are strengthening our ability to deliver the next generation of biological solutions. This move enhances our end-to-end innovation pipeline and reinforces ICL's role in advancing sustainable agriculture at scale."
About Evogene Ltd.
Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique technological engines 鈥� MicroBoost AI, ChemPass AI, and GeneRator AI 鈥� leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd., and ag-biologicals by Lavie Bio Ltd. For more information, please visit .
Forward Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates," or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss Lavie Bio's future operation and commercialization of its ag-biological solutions at scale, and future revenues resulting from the assets which are not acquired by ICL. Such statements are based on current expectations, estimates, projections, and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Evogene Investors听Relations Contact:
Email: [email protected]
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
听
View original content:
SOURCE Evogene
FAQ
What assets did Evogene (EVGN) sell to ICL in the Lavie Bio transaction?
What did Evogene retain from the Lavie Bio sale to ICL?
How does the Lavie Bio acquisition benefit ICL?
What is the strategic significance of Evogene's Lavie Bio sale to ICL?
When was the Lavie Bio sale agreement originally announced?
